%0 Journal Article
%T Symptomatic Clusters Related to Amyloid Positivity in Cognitively Unimpaired Individuals.
%A Sannemann L
%A Bartels C
%A Brosseron F
%A Buerger K
%A Fliessbach K
%A Freiesleben SD
%A Frommann I
%A Glanz W
%A Heneka MT
%A Janowitz D
%A Kilimann I
%A Kleineidam L
%A Lammerding D
%A Laske C
%A Munk MHJ
%A Perneczky R
%A Peters O
%A Priller J
%A Rauchmann BS
%A Rostamzadeh A
%A Roy-Kluth N
%A Schild AK
%A Schneider A
%A Schneider LS
%A Spottke A
%A Spruth EJ
%A Teipel S
%A Wagner M
%A Wiltfang J
%A Wolfsgruber S
%A Duezel E
%A Jessen F
%A  
%J J Alzheimers Dis
%V 100
%N 1
%D 2024 Jun 5
%M 38848176
%F 4.16
%R 10.3233/JAD-231335
%X <B>UNASSIGNED: </B>The NIA-AA Research Framework on Alzheimer's disease (AD) proposes a transitional stage (stage 2) characterized by subtle cognitive decline, subjective cognitive decline (SCD) and mild neurobehavioral symptoms (NPS).<BR><B>UNASSIGNED: </B>To identify participant clusters based on stage 2 features and assess their association with amyloid positivity in cognitively unimpaired individuals.<BR><B>UNASSIGNED: </B>We included baseline data of N = 338 cognitively unimpaired participants from the DELCODE cohort with data on cerebrospinal fluid biomarkers for AD. Classification into the AD continuum (i.e., amyloid positivity, A+) was based on Aβ42/40 status. Neuropsychological test data were used to assess subtle objective cognitive dysfunction (OBJ), the subjective cognitive decline interview (SCD-I) was used to detect SCD, and the Neuropsychiatric Inventory Questionnaire (NPI-Q) was used to assess NPS. A two-step cluster analysis was carried out and differences in AD biomarkers between clusters were analyzed.<BR><B>UNASSIGNED: </B>We identified three distinct participant clusters based on presented symptoms. The highest rate of A+ participants (47.6%) was found in a cluster characterized by both OBJ and SCD. A cluster of participants that presented with SCD and NPS (A+:26.6%) and a cluster of participants with overall few symptoms (A+:19.7%) showed amyloid positivity in a range that was not higher than the expected A+ rate for the age group. Across the full sample, participants with a combination of SCD and OBJ in the memory domain showed a lower Aβ42/ptau181 ratio compared to those with neither SCD nor OBJ.<BR><B>UNASSIGNED: </B>The cluster characterized by participants with OBJ and concomitant SCD was enriched for amyloid pathology.